(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
The AIM-traded firm said the data, presented at the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE